# Perioperative Cardiac Risk Management for Noncardiac Surgery


## Guidelines

### Key sources
The following summarized guidelines for the evaluation and management of perioperative cardiac risk management for noncardiac surgery are prepared by our editorial team based on guidelines from the Society of Cardiovascular Computed Tomography (SCCT/SVM/SCMR/SCA/AHA/ASNC/HRS/ACC/ACS 2024), the European Society for Vascular Surgery (ESVS 2023), the European Society of Anaesthesiology and Intensive Care (ESAIC 2023), the European Society of Cardiology (ESC 2023,2022,2021), the American College of Chest Physicians (ACCP 2022), the Society for Cardiovascular Angiography and Interventions (SCAI/AHA/ACC 2022), the American Heart Association (AHA/ACC 2021), and the Canadian Cardiovascular Society (CCS 2017).

## Studies

### 2024 • Stop-or-Not
In patients who were being treated with a renin-angiotensin system inhibitors for at least 3 months and were scheduled to undergo a major noncardiac surgery, continuation of RAS inhibitors were not superior to discontinuation of RAS inhibitors with respect to the rate of death from all causes and major postoperative complications within 28 days after surgery.
*Matthieu Legrand et al. JAMA. 2024 Sep 24.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/39320895/)

### 2024 • IMPROVE
In patients undergoing major noncardiac surgery, personalized BP management was not superior to routine BP management with respect to the rate of neurocognitive disorders between postoperative days 3 and 7.
*Julia Y Nicklas et al. BJA Open. 2024 Jul 1:11:100294.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/39086783/)

### 2022 • POISE-3 (original research)
In patients undergoing noncardiac surgery, tranexamic acid was superior to placebo with respect to the composite outcome of life-threatening bleeding, major bleeding, or bleeding into a critical organ at 30 days.
*P J Devereaux et al. N Engl J Med. 2022 May 26.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/35614323/)

### 2019 • PROBESE
In adult patients with body mass indices ≥ 35 and substantial risk for postoperative pulmonary complications who were undergoing noncardiac, nonneurological surgery under general anesthesia, high level of PEEP was not superior to low level of PEEP with respect to the rate of postoperative pulmonary complications within the first 5 days.
*Writing Committee for the PROBESE Collaborative Group of the PROtective VEntilation Network (PROVEnet) for the Clinical Trial Network of the European Society of Anaesthesiology et al. JAMA. 2019 Jun 18.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/31211342/)

### 2018 • MANAGE
In patients who had undergone noncardiac surgery and were within 35 days of myocardial injury after noncardiac surgery, dabigatran was superior to placebo with respect to major vascular complications.
*Devereaux PJ et al. Lancet. 2018 Jun 9.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/29861185/)

### 2014 • POISE-2 (clonidine)
In patients with, or at risk for, atherosclerotic disease who were undergoing noncardiac surgery, clonidine was not superior to placebo with respect to death or nonfatal myocardial infarction at 30 days.
*Devereaux PJ et al. N Engl J Med. 2014 Apr 17.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/24679060/)

### 2014 • POISE-2 (aspirin)
In patients undergoing noncardiac surgery who were at risk for vascular complications, aspirin was not superior to placebo with respect to death or nonfatal myocardial infarction at 30 days.
*Devereaux PJ et al. N Engl J Med. 2014 Apr 17.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/24679062/)

### 2008 • POISE 1
In patients with, or at risk of, atherosclerotic disease who were undergoing noncardiac surgery, metoprolol succinate was superior to placebo with respect to cardiovascular death, nonfatal myocardial infarction, or nonfatal cardiac arrest, at 30 days.
*POISE Study Group et al. Lancet. 2008 May 31.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/18479744/)

### 2004 • CARP
In patients at increased risk for perioperative cardiac complications and clinically significant coronary artery disease, coronary artery revascularization was not superior to no revascularization with respect to the rate of death at a mean follow-up of 2.7 years.
*McFalls EO et al. N Engl J Med. 2004 Dec 30.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/15615804/)

## Classification and Risk Stratification

### Cardiac Risk Assessment

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Use a validated risk-prediction tool to estimate the risk of perioperative major adverse cardiovascular events in patients with known CVD undergoing NCS. (B)
- Consider obtaining a structured assessment of functional capacity, such as the Duke Activity Status Index, to stratify the risk of perioperative adverse cardiovascular events in patients undergoing elevated-risk NCS. (C)

### Duke Activity Status Index (DASI)

**Calculator Available**

**Questions:**
- Is the patient able to take care of self (such as eating, dressing, bathing, using the toilet)?
- Is the patient able to walk indoors?
- Is the patient able to walk 1-2 blocks on level ground?
- Is the patient able to climb a flight of stairs or walk up a hill?
- Is the patient able to run a short distance?
- Is the patient able to do light work around the house (such as dusting, washing dishes)?
- Is the patient able to do moderate work around the house (such as vacuuming, sweeping, carrying groceries)?
- Is the patient able to do heavy work around the house (such as scrubbing floors, moving furniture)?
- Is the patient able to do yardwork (such as raking leaves, weeding, mowing)?
- Is the patient able to have sexual relations?
- Is the patient able to participate in moderate recreational activities (such as golf, bowling, dancing)?
- Is the patient able to participate in strenuous sports (such as swimming, singles tennis)?

**Calculation:**
- DASI score (the higher the score, the higher the functional status): 58.20
- Metabolic equivalents (METs): 9.9

**As per ESC 2022 guidelines:**
- Obtain preoperative risk assessment, ideally at the same time as the NCS is proposed. (B)

**As per CCS 2017 guidelines:**
- Do not delay surgery for preoperative cardiac risk assessment in patients requiring emergency surgery. (D)
- Obtain preoperative cardiac risk assessment in patients requiring urgent or semi-urgent surgery only if history or physical examination suggests a potential undiagnosed severe obstructive intracardiac abnormality, severe pulmonary hypertension, or an unstable cardiovascular condition. (E)
- Obtain preoperative cardiac risk assessment in patients undergoing elective NCS aged 45 years or 18-44 years with known significant CVD. (E)
- Consider using the RCRI over other available clinical risk prediction scores when evaluating cardiac risk. (C)

### Revised Cardiac Risk Index for Perioperative Risks (RCRI)

**Calculator Available**

**Risk Factors:**
- High-risk surgery (intraperitoneal, intrathoracic, or suprainguinal vascular surgery)
- History of ischemic heart disease (history of myocardial infarction/positive exercise test, ECG with pathological Q waves, current ischemic chest pain, or use of nitrate)
- History of congestive heart failure (pulmonary edema, bilateral rales or S3 gallop, paroxysmal nocturnal dyspnea, pulmonary vascular redistribution on chest X-ray)
- History of cerebrovascular disease (transient ischemic attack or stroke)
- Use of insulin for diabetes
- Preoperative creatinine > 2 mg/dL [> 178 mcmol/L]

**Interpretation:**
- Score: 0 points
- Risk of 30-day MI, cardiac arrest or mortality is 3.9%

### Frailty Assessment
**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider obtaining preoperative frailty assessment using a validated tool to evaluate perioperative risk and guide management in all patients aged ≥ 65 years and in patients aged < 64 years with perceived frailty undergoing elevated-risk NCS. (C)

## Diagnostic Investigations

### History and Physical Examination

**As per ESC 2022 guidelines:**
- Elicit an accurate history and obtain a clinical assessment in all patients scheduled for NCS. (B)
- Obtain further diagnostic evaluation before elective NCS in the presence of chest pain or other symptoms suggestive of undetected coronary artery disease. Obtain a multidisciplinary assessment to guide the choice of treatment with the lowest total risk for the patient. (B)
- Obtain preoperative screening for hypertension-mediated organ damage and cardiovascular risk factors in patients with newly diagnosed hypertension scheduled for elective high-risk NCS. (Class I, Level C) Do not defer NCS in patients with stage I-II hypertension. (B)
- Consider obtaining frailty screening using a validated screening tool in ≥ 70 years old patients scheduled to undergo intermediate- or high-risk NCS. (C)

### ECG - Low-Risk Patients

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Do not obtain routine preoperative resting 12-lead ECG in asymptomatic patients undergoing low-risk surgical procedures. (D)

**As per ESC 2022 guidelines:**
- Do not obtain routine preoperative ECG in low-risk patients undergoing low- or intermediate-risk NCS. (D)
- Consider obtaining an ECG before high-risk NCS in patients aged 45-65 years without signs, symptoms, or history of CVD. (C)

### ECG - High-Risk Patients

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Obtain a preoperative resting 12-lead ECG to establish a preoperative baseline and guide perioperative management in patients with known coronary heart disease, significant arrhythmia, peripheral arterial disease, cerebrovascular disease, other significant structural heart disease, or symptoms of CVD undergoing elevated-risk surgery. (B)
- Consider obtaining a preoperative resting 12-lead ECG to establish a preoperative baseline and guide perioperative management in asymptomatic patients undergoing elevated-risk surgeries without known CVD. (C)
- Obtain further evaluation to refine cardiovascular risk assessment in patients undergoing NCS with a preoperative ECG exhibiting new abnormalities. (B)

**As per ESC 2022 guidelines:**
- Obtain a 12-lead ECG before intermediate- or high-risk NCS in patients with known CVD or cardiovascular risk factors (including age ≥ 65 years), or symptoms/signs suggestive of CVD. (B)
- Obtain an ECG before NCS in patients with dyspnea and/or peripheral edema unless there is a certain noncardiac explanation. (B)
- Obtain an ECG before NCS in patients with a family history of genetic cardiomyopathy, regardless of age and symptoms. (B)

### Cardiac Biomarkers

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Obtain BNP or NT-proBNP before surgery to supplement perioperative risk assessment in patients with known CVD, or age ≥ 65 years, or age ≥ 45 years with symptoms suggestive of CVD undergoing elevated-risk NCS. (B)
- Consider obtaining cardiac troponin before surgery to supplement perioperative risk assessment in patients with known CVD, or age ≥ 65 years, or age ≥ 45 years with symptoms suggestive of CVD undergoing elevated-risk NCS. (C)

**As per ESAIC 2023 guidelines:**
- Consider obtaining a routine preoperative measurement of cardiac troponins to help evaluate the risk of certain adverse outcomes before and after NCS. (C)
- Consider obtaining cardiac troponins in addition to clinical risk scores for the prediction of certain postoperative events. (C)
- Consider obtaining a routine measurement of preoperative BNPs to help evaluate the risk of certain adverse outcomes in NCS. (C)
- Consider obtaining BNPs in addition to clinical risk scores to improve the prediction of certain postoperative events, particularly 30-day major adverse cardiac events. (C)

**As per ESC 2022 guidelines:**
- Do not obtain routine preoperative high-sensitivity cardiac troponin T/I or BNP/NT-proBNP testing in low-risk patients undergoing low- and intermediate-risk NCS. (D)
- Consider obtaining cardiac biomarkers before high-risk NCS in 45-65 years old patients without signs, symptoms, or history of CVD. (C)
- Obtain NT-proBNP/BNP testing before NCS in patients with dyspnoea and/or peripheral edema unless there is a certain noncardiac explanation. (B)
- Obtain high-sensitivity cardiac troponin T/I testing before intermediate- or high-risk NCS and at 24 hours and 48 hours afterward in patients with known CVD, cardiovascular risk factors (including age ≥ 65 years), or symptoms suggestive of CVD. (B)
- Consider obtaining BNP or NT-proBNP testing before intermediate- or high-risk NCS in patients with known CVD, cardiovascular risk factors (including age ≥ 65 years), or symptoms suggestive of CVD. (C)
- Obtain NT-proBNP/BNP testing (if not obtained recently) in patients with suspected or known HF scheduled for high-risk NCS. (B)

**As per CCS 2017 guidelines:**
- Obtain NT-proBNP or BNP before NCS to enhance perioperative cardiac risk estimation in patients aged ≥ 65 years or 45-64 years with significant CVD, or having a RCRI score ≥ 1. (B)

### Echocardiography

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Obtain preoperative evaluation of LV function to guide perioperative management in patients with new dyspnea, physical examination findings of HF, or suspected new/worsening ventricular dysfunction undergoing NCS. (B)
- Consider obtaining preoperative assessment of LV function to guide perioperative management in patients with a known diagnosis of HF with worsening dyspnea or other change in clinical status undergoing NCS. (C)
- Do not obtain routine preoperative evaluation of LV function in asymptomatic and clinically stable patients undergoing NCS due to lack of benefit. (D)

**As per ESC 2022 guidelines:**
- Do not obtain routine preoperative assessment of LV function. (D)
- Consider obtaining a TTE before high-risk NCS in patients with suspected new CVD or unexplained signs or symptoms. (C)
- Obtain a TTE before NCS in patients with a newly detected murmur and symptoms/signs of CVD. (B)
- Obtain a TTE before high-risk NCS in patients with a newly detected murmur suggesting clinically significant pathology. (B)
- Consider obtaining a TTE before moderate-risk NCS in patients with a newly detected murmur but without other signs/symptoms of CVD. (C)
- Obtain a TTE before NCS in patients with dyspnea and/or peripheral edema and elevated NT-proBNP/BNP. (B)
- Obtain a TTE in patients with suspected or known HF scheduled for high-risk NCS. (B)
- Obtain a TTE in patients with poor functional capacity and/or high NT-proBNP/BNP or if murmurs are detected before high-risk NCS, in order to undertake risk-reduction strategies. (B)
- Consider obtaining a TTE before intermediate-risk NCS in patients with poor functional capacity, abnormal ECG, high NT-proBNP/BNP, or ≥ 1 clinical risk factor. (C)
- Consider obtaining focused cardiac ultrasound by trained specialists as an alternative to TTE for preoperative triage to avoid delaying surgery. (C)

**As per CCS 2017 guidelines:**
- Do not obtain preoperative resting echocardiography to enhance perioperative cardiac risk estimation. (D)

### Stress Testing

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider obtaining stress testing to evaluate for inducible myocardial ischemia in patients undergoing elevated-risk NCS with poor or unknown functional capacity and elevated risk for perioperative cardiovascular events based on a validated risk tool. (C)
- Do not obtain routine stress testing before NCS in patients at low risk for perioperative cardiovascular events, with adequate functional capacity and stable symptoms, or undergoing low-risk procedures due to lack of benefit. (D)

**As per ESC 2022 guidelines:**
- Do not obtain routine stress imaging before NCS. (D)
- Obtain stress imaging before high-risk elective NCS in patients with poor functional capacity and a high likelihood of coronary artery disease or high clinical risk. (B)
- Consider obtaining stress imaging before high-risk NCS in asymptomatic patients with poor functional capacity and previous PCI or CABG. (C)
- Consider obtaining stress imaging before intermediate-risk NCS when ischemia is of concern in patients with clinical risk factors and poor functional capacity. (C)

**As per CCS 2017 guidelines:**
- Do not obtain preoperative exercise stress testing or cardiopulmonary exercise testing to enhance perioperative cardiac risk estimation. (D)
- Do not obtain preoperative pharmacological stress imaging, either echocardiography or radionuclide imaging, to enhance perioperative cardiac risk estimation. (D)

### Coronary CTA

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider obtaining coronary CTA in patients undergoing elevated-risk surgery with poor or unknown functional capacity and elevated risk for perioperative cardiovascular events based on a validated risk tool. (C)
- Do not obtain routine coronary CTA before NCS in patients at low risk for perioperative cardiovascular events, with adequate functional capacity and stable symptoms, or undergoing low-risk procedures due to lack of benefit. (D)

**As per ESC 2022 guidelines:**
- Consider obtaining coronary CTA to rule out coronary artery disease in patients with suspected chronic coronary syndrome or biomarker-negative non-ST-segment elevation ACS in case of low-to-intermediate clinical likelihood of coronary artery disease or in patients unsuitable for noninvasive functional testing undergoing non-urgent intermediate- or high-risk NCS. (C)

**As per CCS 2017 guidelines:**
- Do not obtain preoperative coronary CTA to enhance perioperative cardiac risk estimation. (D)

### Hemoglobin Levels

**As per ESC 2022 guidelines:**
- Obtain preoperative measurement of hemoglobin level in patients scheduled for intermediate- or high-risk NCS. (B)
- Treat anemia in advance of NCS to reduce the need for RBC transfusion during surgery. (A)
- Consider using an algorithm for the diagnosis and treatment of patients with anemia before NCS. (B)

### Screening for Sleep Obstructive Apnea
**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider obtaining screening for obstructive sleep apnea using validated questionnaires to assess the risk of perioperative complications in patients scheduled for NCS. (C)

## Diagnostic Procedures

### Coronary Angiography

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Do not obtain routine preoperative invasive coronary angiography in patients undergoing NCS. (D)

**As per ESC 2022 guidelines:**
- Use the same indications for invasive coronary angiography and revascularization preoperatively as in the non-surgical setting. (B)
- Do not obtain routine preoperative invasive coronary angiography in patients with stable chronic coronary syndrome undergoing low- or intermediate-risk NCS. (D)
- Consider obtaining preoperative invasive coronary angiography in patients with stable chronic coronary syndrome undergoing elective surgical carotid endarterectomy. (C)

## Medical Management

### General Principles
**As per ESC 2022 guidelines:**
- Optimize guideline-recommended treatment of CVD and cardiovascular risk factors before NCS if time allows. (B)
- Control cardiovascular risk factors, including BP, dyslipidemia, and diabetes, before NCS. (B)

### Management of Hypertension

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider continuing medical therapy for hypertension throughout the perioperative period in most patients with hypertension planned for elective NCS. (C)
- Consider deferring elective elevated-risk surgery in patients with cardiovascular risk factors for perioperative complications and recent history of poorly controlled hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg before the day of surgery) to reduce the risk of perioperative complications. (C)
- Resume preoperative antihypertensive medications in patients with hypertension as soon as clinically reasonable after NCS to avoid complications from postoperative hypertension. (B)

### Management of Beta-Blockers

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Continue β-blockers through the perioperative period as appropriate based on clinical circumstances in patients on stable doses of β-blockers undergoing NCS. (B)

**As per ESC 2022 guidelines:**
- Continue β-blockers in the perioperative period in patients currently receiving β-blockers. (B)

**As per CCS 2017 guidelines:**
- Consider continuing β-blockers during the perioperative period in patients taking β-blockers chronically. (C)

### Management of RAAS Inhibitors

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider omitting RAAS inhibitors 24 hours before surgery in selected patients on chronic therapy for hypertension undergoing elevated-risk NCS to limit intraoperative hypotension. (C)
- Continue RAAS inhibitors perioperatively in patients on chronic therapy for HFrEF. (B)

**As per ESC 2022 guidelines:**
- Consider continuing RAAS inhibitors in the perioperative period in patients with stable HF. (C)
- Consider withholding RAAS inhibitors on the day of NCS to prevent perioperative hypotension in patients without HF. (C)

**As per CCS 2017 guidelines:**
- Withhold ACEis/ARBs starting 24 hours before NCS in patients treated chronically with ACEis/ARBs. (B)

**Landmark Trial: Stop-or-Not**
In patients who were being treated with a renin-angiotensin system inhibitors for at least 3 months and were scheduled to undergo a major noncardiac surgery, continuation of RAS inhibitors were not superior to discontinuation of RAS inhibitors with respect to the rate of death from all causes and major postoperative complications within 28 days after surgery.
*Matthieu Legrand et al. JAMA. 2024 Sep 24.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/39320895/)

### Management of Statins

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Continue statin therapy to reduce the risk of major adverse cardiovascular events in patients currently on statins and scheduled for NCS. (B)

**As per ESC 2022 guidelines:**
- Continue statins in the perioperative period in patients already receiving statins. (B)
- Consider initiating statins in the perioperative period in patients with an indication for statin therapy. (C)

**As per CCS 2017 guidelines:**
- Continue statin therapy in the perioperative period in patients receiving chronic statin therapy. (B)

### Management of Antiplatelets

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Determine management of perioperative antiplatelet therapy and timing of surgery in patients with coronary artery disease undergoing elective NCS through a multidisciplinary team with shared decision-making to weigh the risks of bleeding, thrombosis, and consequences of delayed surgery. (B)
- Consider continuing aspirin in selected patients with chronic coronary disease without prior PCI undergoing elective NCS when the risk of cardiac events outweighs the risk of bleeding. (C)
- Do not initiate aspirin routinely in patients with coronary artery disease without prior PCI undergoing elective noncarotid NCS. (D)
- Continue aspirin (75-100 mg), if possible, to reduce the risk of cardiac events in patients with prior PCI undergoing NCS. (B)
- Continue dual antiplatelet therapy in patients with coronary artery disease requiring time-sensitive NCS within 30 days of PCI with bare-metal stent or < 3 months of PCI with drug-eluting stent, unless the risk of bleeding outweighs the benefit of preventing stent thrombosis. (B)
- Substitute aspirin when feasible in the perioperative period until oral anticoagulation can be safely reinitiated in patients with prior PCI requiring discontinuation of oral anticoagulation monotherapy before NCS. (B)
- Consider administering perioperative bridging with IV antiplatelet therapy in selected patients after PCI (< 6 months after drug-eluting stent placement or < 30 days after bare-metal stent placement) having a high thrombotic risk, if NCS cannot be deferred. (C)

**As per ACCP 2022 guidelines:**
- Avoid obtaining routine platelet function testing before surgery/procedure to guide perioperative antiplatelet management in patients receiving antiplatelet drug therapy and undergoing elective surgery/procedure. (D)
- Consider continuing antiplatelet drugs in patients on antiplatelet therapy undergoing minor dental, dermatologic, or ophthalmologic procedures. (C)
- Consider continuing aspirin in patients on aspirin therapy undergoing elective NCS. (C)
- Consider interrupting aspirin ≤ 7 days before surgery in patients on aspirin therapy undergoing elective surgery and requiring aspirin interruption. (C)
- Consider interrupting clopidogrel 5 days before surgery in patients receiving clopidogrel and undergoing elective NCS. (C)
- Consider interrupting ticagrelor 3-5 days before surgery in patients receiving ticagrelor and undergoing elective NCS. (C)
- Consider interrupting prasugrel 7 days before surgery in patients receiving prasugrel and undergoing elective NCS. (C)
- Consider continuing aspirin in patients on aspirin therapy undergoing CABG surgery. Consider interrupting P2Y12 inhibitors in patients on P2Y12 inhibitor therapy. (C)
- Consider continuing both antiplatelet agents or interrupting one antiplatelet agent within 7-10 days of surgery in patients on aspirin and P2Y12 inhibitor therapy with coronary stents placed within the last 6-12 weeks undergoing elective surgery/procedure. (C)
- Consider interrupting P2Y12 inhibitors before surgery in patients on aspirin and P2Y12 inhibitor therapy with coronary stents placed within the last 3-12 months undergoing elective surgery/procedure. (C)
- Consider delaying the elective surgery/procedure in patients with coronary stents requiring continued dual antiplatelet therapy. (C)
- Avoid administering routine bridging therapy with a glycoprotein IIb-IIIa inhibitor, cangrelor, or LMWH in patients with coronary stents requiring interruption of antiplatelet drugs for an elective surgery/procedure. (D)
- Consider resuming antiplatelet drugs ≤ 24 hours after surgery/procedure in patients requiring antiplatelet drug interruption for an elective surgery/procedure. (C)
- Consider resuming aspirin or P2Y12 inhibitors within 24 hours after surgery in patients on aspirin or P2Y12 inhibitor therapy undergoing CABG surgery. (C)

**As per ESC 2022 guidelines:**
- Discuss the management of antiplatelet therapy between the surgeon, anesthesiologist, and cardiologist in patients with a recent PCI scheduled for NCS. (B)
- Consider initiating dual antiplatelet therapy for at least 3 months before time-sensitive NCS in high-risk patients with a recent PCI (such as patients with STEMI or high-risk non-ST-segment elevation ACS). (C)
- Continue aspirin perioperatively in patients with a previous PCI if the bleeding risk allows. (B)
- Withhold ticagrelor for 3-5 days, clopidogrel for 5 days, and prasugrel for 7 days before NCS if interruption of P2Y12 inhibitor is indicated. (B)
- Interrupt aspirin for at least 7 days preoperatively in patients undergoing high bleeding risk surgery (such as intracranial, spinal neurosurgery, or vitreoretinal eye surgery). (B)
- Consider interrupting aspirin for at least 3 days before NCS to reduce the risk of bleeding (if the bleeding risk outweighs the ischemic risk) in patients without a history of PCI. (C)
- Restart therapy as soon as possible (within 48 hours) after surgery, according to interdisciplinary risk assessment, if antiplatelet therapy has been interrupted before surgery. (B)

**As per CCS 2017 guidelines:**
- Do not continue aspirin to prevent perioperative cardiac events, except in patients with a recent coronary artery stenting and patients undergoing carotid endarterectomy. (D)

### Management of Anticoagulants - General Principles
**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Use a multidisciplinary team-based approach to time-based interruption in patients with CVD receiving oral anticoagulation and requiring elective NCS to balance the competing risks of thromboembolism and perioperative bleeding. (B)

### Management of Anticoagulants - VKAs, Elective Surgeries/Procedures

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider administering preoperative bridging with parenteral heparin to reduce thromboembolic risk in patients with CVD and high thrombotic risk undergoing NCS and requiring VKA interruption. (C)

**As per ACCP 2022 guidelines:**
- Consider interrupting VKAs (warfarin) ≥ 5 days before an elective surgery/procedure in patients requiring VKA (warfarin) interruption for an elective surgery/procedure. (C)
- Consider resuming VKA (warfarin) within 24 hours after an elective surgery/procedure in patients requiring VKA (warfarin) interruption for an elective surgery/procedure. (C)
- Consider resuming the first postoperative VKA dose at the patient's usual dose in patients requiring VKA (warfarin) interruption for an elective surgery/procedure. (C)
- Avoid administering routine preoperative vitamin K in patients requiring VKA interruption for an elective surgery/procedure having an elevated INR (> 1.5) -2 days before surgery/procedure. (D)
- Do not administer heparin bridging in patients receiving VKA therapy for AF requiring VKA interruption for an elective surgery/procedure. (D)
- Avoid administering heparin bridging in patients receiving VKA therapy for VTE as the sole clinical indication requiring VKA interruption for an elective surgery/procedure. (D)
- Consider administering heparin bridging in patients receiving VKA therapy deemed at high risk for thromboembolism and requiring VKA interruption for an elective surgery/procedure. (C)
- Avoid administering heparin bridging in patients receiving VKA therapy deemed at low-to-moderate risk for thromboembolism and requiring VKA interruption for an elective surgery/procedure. (D)

### Management of Anticoagulants - VKAs, Minor Procedures

**As per ACCP 2022 guidelines:**
- Consider continuing VKAs in patients receiving VKA therapy and requiring a dental, minor dermatologic, or ophthalmologic procedure. (C)
- Consider using a pro-hemostatic agent with the continuation of VKA over alternative management options (such as discontinuation of VKA with or without heparin bridging) in patients receiving VKA therapy and requiring a dental procedure. (C)
- Continue VKAs in patients receiving VKA therapy and requiring a pacemaker or internal cardiac defibrillator implantation. (B)
- Avoid administering heparin bridging during the period of VKA interruption in patients receiving VKA therapy and requiring VKA interruption for colonoscopy with anticipated polypectomy. (D)

### Management of Anticoagulants - Heparins

**As per ACCP 2022 guidelines:**
- Consider interrupting UFH ≥ 4 hours before a surgery/procedure in patients receiving therapeutic-dose IV UFH bridging for an elective surgery/procedure. (C)
- Consider resuming UFH ≥ 24 hours after a surgery/procedure in patients receiving therapeutic-dose IV UFH bridging for an elective surgery/procedure. (C)
- Consider administering the last preoperative LMWH bridging dose at approximately 24 hours before a surgery/procedure in patients receiving LMWH bridging for an elective surgery/procedure. (C)
- Consider administering the first postoperative LMWH bridging dose at least 24 hours after a surgery/procedure in patients receiving LMWH bridging for an elective surgery/procedure. (C)
- Consider administering half the total daily dose of LMWH the day before surgery/procedure in patients receiving LMWH bridging for an elective surgery/procedure. (C)
- Avoid obtaining routine measurements of anti-factor Xa levels to guide perioperative LMWH management in patients receiving LMWH bridging for an elective surgery/procedure. (D)

**As per ESC 2022 guidelines:**
- Administer LMWH as an alternative to UFH for bridging in patients with mechanical heart valves and high surgical risk. (B)
- Consider administering UFH or LMWH for bridging (if interruption of oral anticoagulation is required) in patients with mechanical prosthetic heart valves undergoing NCS and having any of the following: mechanical aortic valve replacement and any thromboembolic risk factor, old-generation mechanical aortic valve replacement, mechanical mitral or tricuspid valve replacement. (C)

### Management of Anticoagulants - DOACs

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Do not administer routine periprocedural bridging in most patients with CVD undergoing elective NCS where OAC interruption is warranted due to increased bleeding risk. (D)
- Consider resuming oral anticoagulation after hemostasis is achieved. (C)

**As per ACCP 2022 guidelines:**
- Consider interrupting apixaban, edoxaban, and rivaroxaban for 1-2 days before surgery/procedure in patients receiving any of these agents requiring elective surgery/procedure. (C)
- Consider interrupting dabigatran for 1-4 days before surgery/procedure in patients receiving dabigatran requiring elective surgery/procedure. (C)
- Avoid administering perioperative heparin bridging in patients requiring DOAC interruption for an elective surgery/procedure. (D)
- Consider resuming DOACs > 24 hours after the surgery/procedure in patients having DOACs interrupted for an elective surgery/procedure. (C)
- Avoid obtaining routine DOAC coagulation function testing to guide perioperative DOAC management in patients having DOACs interrupted for an elective surgery/procedure. (D)

**As per ESC 2022 guidelines:**
- Interrupt DOACs immediately when an urgent surgical intervention is required. (B)
- Consider administering idarucizumab in patients on dabigatran and requiring urgent surgical intervention with intermediate-to-high bleeding risk. (C)
- Use an interruption regimen for non-minor bleeding risk procedures in patients on DOACs based on the DOAC compound, renal function, and bleeding risk. (B)
- Consider interrupting DOACs for up to 5 half-lives and re-initiating after 24 hours for interventions with a very high risk of bleeding, such as spinal or epidural anesthesia. (C)
- Consider administering prothrombin complex concentrate or activated prothrombin complex concentrate for reversing DOAC effects when specific reversal agents are unavailable. (C)
- Consider obtaining specific coagulation tests and assessment of DOAC plasma levels to interpret routine coagulation tests and waning of anticoagulant effect in patients requiring urgent surgical interventions. (C)
- Do not interrupt OAC therapy for minor bleeding risk surgeries and other procedures where bleeding can be easily controlled. (D)
- Perform minor bleeding risk procedures at trough levels, typically 12-24 hours after the last intake, in patients on DOACs. (D)
- Do not administer bridging for OAC therapy in patients with low/moderate thrombotic risk undergoing NCS. (D)
- Do not use reduced-dose DOACs to attenuate the risk of postoperative bleeding. (D)
- Consider postponing therapeutic anticoagulation 48-72 hours after surgery if the bleeding risk with the resumption of full-dose anticoagulation outweighs the risk of thromboembolic events. Administer postoperative thromboprophylaxis until the resumption of the full OAC dose is deemed safe. (C)

### Management of Diuretics
**As per ESC 2022 guidelines:**
- Consider discontinuing diuretics transiently on the day of NCS in patients receiving diuretics hypertension. (C)

### Management of SGLT-2 Inhibitors

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Discontinue SGLT-2 inhibitors 3-4 days before NCS to reduce the risk of perioperative metabolic acidosis. (B)

**As per ESC 2022 guidelines:**
- Consider interrupting SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS. (C)

### Prophylactic Beta-Blockers

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider initiating β-blockers in patients scheduled for elective NCS and having a new indication for β-blockade, ensuring initiation occurs far enough before surgery (optimally > 7 days) to permit assessments of tolerability and drug titration if needed. (C)
- Do not initiate β-blockers on the day of surgery in patients undergoing NCS with no immediate need for β-blockers due to increased risk for postoperative mortality. (D)

**As per ESC 2022 guidelines:**
- Do not initiate routine β-blocker therapy in the perioperative period, including for the prevention of postoperative AF. (D)
- Consider initiating β-blockers before high-risk NCS to reduce the incidence of perioperative myocardial infarction in patients with ≥ 2 clinical risk factors. (B)
- Consider initiating β-blockers before NCS in patients with known coronary artery disease or myocardial ischemia. (C)

**Landmark Trial: POISE 1**
In patients with, or at risk of, atherosclerotic disease who were undergoing noncardiac surgery, metoprolol succinate was superior to placebo with respect to cardiovascular death, nonfatal myocardial infarction, or nonfatal cardiac arrest, at 30 days.
*POISE Study Group et al. Lancet. 2008 May 31.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/18479744/)

**As per CCS 2017 guidelines:**
- Do not administer β-blockers within 24 hours before NCS. (D)

### Prophylactic Alpha-2 Agonists

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Do not administer low-dose clonidine perioperatively to reduce cardiovascular risk in patients undergoing NCS. (D)

**Landmark Trial: POISE-2 (clonidine)**
In patients with, or at risk for, atherosclerotic disease who were undergoing noncardiac surgery, clonidine was not superior to placebo with respect to death or nonfatal myocardial infarction at 30 days.
*Devereaux PJ et al. N Engl J Med. 2014 Apr 17.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/24679060/)

**As per CCS 2017 guidelines:**
- Do not administer preoperative α-2 agonists for the prevention of perioperative cardiovascular events. (D)

### Prophylactic CCBs
**As per CCS 2017 guidelines:**
- Avoid administering CCBs for the prevention of perioperative cardiovascular events. (D)

### Prophylactic Statins
**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Initiate statin therapy perioperatively, with the intention of long-term use, in statin-naïve adult patients meeting criteria for statin use based on ASCVD history or 10-year risk assessment and scheduled for NCS. (B)

### Prophylactic Aspirin
**As per CCS 2017 guidelines:**
- Do not administer aspirin for the prevention of perioperative cardiac events. (D)

**Landmark Trial: POISE-2 (aspirin)**
In patients undergoing noncardiac surgery who were at risk for vascular complications, aspirin was not superior to placebo with respect to death or nonfatal myocardial infarction at 30 days.
*Devereaux PJ et al. N Engl J Med. 2014 Apr 17.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/24679062/)

### Prophylactic Tranexamic Acid
**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider administering tranexamic acid to reduce intraoperative blood loss, reduce transfusions, and avoid anemia in patients undergoing NCS with expected blood loss. (B)

## Nonpharmacologic Interventions

### Smoking Cessation

**As per ESC 2022 guidelines:**
- Advise smoking cessation > 4 weeks before NCS to reduce postoperative complications and mortality. (B)

**As per CCS 2017 guidelines:**
- Discuss and facilitate smoking cessation before NCS. (B)

## Therapeutic Procedures

### Pulmonary Artery Catheterization

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Do not perform pulmonary artery catheterization routinely to reduce morbidity or mortality in patients with CVD undergoing NCS. (D)
- Consider performing pulmonary artery catheterization in patients with CVD undergoing NCS when underlying medical conditions significantly affecting hemodynamics (such as decompensated HF, severe valvular disease, combined shock states, pulmonary hypertension) cannot be corrected before surgery. (C)

**As per CCS 2017 guidelines:**
- Do not perform pulmonary artery catheterization in patients undergoing NCS. (D)

### Mechanical Circulatory Support
**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider using temporary mechanical circulatory support devices preemptively or as rescue therapy in patients with acute, severe hemodynamic instability and cardiopulmonary dysfunction undergoing urgent or emergency NCS. (C)

## Perioperative Care

### Choice of Anesthesia

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider administering either a volatile-based anesthetic agent or total IV anesthesia for general anesthesia in patients undergoing NCS, with no apparent difference in associated cardiovascular events (myocardial infarction, ischemia). (B)
- Consider administering either neuraxial or general anesthesia in patients undergoing NCS where neuraxial is feasible, with no apparent difference in associated cardiovascular events. (C)

### Hemodynamic Monitoring

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider obtaining perioperative TEE or focused cardiac ultrasound, if expertise is readily available, to determine the cause in patients with unexplained hemodynamic instability undergoing NCS. (C)
- Do not obtain routine intraoperative TEE to screen for cardiac abnormalities or to monitor for myocardial ischemia in patients without risk factors or procedural risks for significant hemodynamic compromise undergoing NCS. (D)

**As per ESC 2022 guidelines:**
- Administer goal-directed hemodynamic therapy to preserve optimal cardiovascular stability in patients undergoing high-risk NCS. (A)
- Assess volume status and signs of organ perfusion regularly in patients with HF undergoing NCS. (B)

### BP Control

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Maintain an intraoperative mean arterial pressure ≥ 60-65 mmHg or SBP ≥ 90 mmHg to reduce the risk of myocardial injury in patients undergoing NCS. (B)
- Treat hypotension (mean arterial pressure < 60-65 mmHg or SBP < 90 mmHg) in the postoperative period after NCS to limit the risk of cardiovascular, cerebrovascular, renal events, and mortality. (B)

**As per ESC 2022 guidelines:**
- Avoid an intraoperative mean arterial pressure decrease of > 20% from baseline values or < 60-70 mmHg for ≥ 10 min to minimize the risk of postoperative organ dysfunction. (D)
- Avoid large perioperative fluctuations in BP, particularly hypotension, during the perioperative period in patients with chronic hypertension undergoing elective NCS. (D)

**Updated Evidence: IMPROVE**
In patients undergoing major noncardiac surgery, personalized BP management was not superior to routine BP management with respect to the rate of neurocognitive disorders between postoperative days 3 and 7.
*Julia Y Nicklas et al. BJA Open. 2024 Jul 1:11:100294.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/39086783/)

### Body Temperature Control
**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider maintaining normothermia to avoid overall perioperative complications in patients with CVD undergoing NCS. (C)

### Thromboprophylaxis

**As per ESC 2022 guidelines:**
- Decide on perioperative thromboprophylaxis for NCS based on individual and procedure-specific risk factors. Choose the type and duration of thromboprophylaxis (LMWH, DOAC, or fondaparinux) based on the type of surgery, duration of immobilization, and patient-related factors. (A)
- Consider administering perioperative thromboprophylaxis in patients at low bleeding risk undergoing total knee or hip arthroplasty for up to 14 or 35 days, respectively. (B)
- Consider administering prophylactic-dose DOACs as an alternative to LMWH after total knee or hip arthroplasty. (B)

### Bleeding Control

**As per ESC 2022 guidelines:**
- Consider using closed-loop arterial blood sampling systems to avoid blood loss. (C)
- Consider maintaining meticulous hemostasis as a routine practice. (C)
- Obtain point-of-care diagnostics for guidance of blood component therapy when available. (A)
- Consider using a feedback/monitoring program or clinical decision support system before blood transfusion. (C)
- Consider obtaining extensive consent about risks associated with transfusion before allogenic blood transfusion. (C)
- Use washed cell salvage in patients undergoing surgery with expected blood loss ≥ 500 mL. (A)
- Consider administering tranexamic acid immediately in patients experiencing major bleeding during NCS. (B)

**Landmark Trial: POISE-3 (original research)**
In patients undergoing noncardiac surgery, tranexamic acid was superior to placebo with respect to the composite outcome of life-threatening bleeding, major bleeding, or bleeding into a critical organ at 30 days.
*P J Devereaux et al. N Engl J Med. 2022 May 26.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/35614323/)

### Pain Management

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider administering epidural analgesia for postoperative pain relief in patients undergoing major abdominal surgery to reduce perioperative cardiac events. (C)
- Consider administering epidural analgesia in patients with a hip fracture waiting for surgical repair to reduce preoperative cardiac events. (C)

**As per ESC 2022 guidelines:**
- Make efforts to avoid postoperative acute pain. (B)
- Do not use non-aspirin NSAIDs as first-line analgesics in patients with established or high risk of CVD. (D)

## Surgical Interventions

### Choice of Surgical Approach
**As per ESC 2022 guidelines:**
- Consider using endovascular or video-assisted approaches in patients with high cardiovascular risk undergoing vascular or pulmonary surgery. (C)

## Specific Circumstances

### Patients with Obesity

**As per ESC 2022 guidelines:**
- Assess cardiorespiratory fitness to estimate perioperative cardiovascular risk in patients with obesity, with particular attention to patients undergoing intermediate- and high-risk NCS. (B)
- Consider obtaining additional specialist assessment before major elective NCS in patients at high risk of obesity hypoventilation syndrome. (C)

### Patients with Diabetes Mellitus

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Obtain preoperative HbA1c testing in patients with or at risk for diabetes scheduled for elective NCS if it has not been obtained in ≤ 3 months. (B)
- Consider continuing metformin during the perioperative period in patients with diabetes or impaired glucose tolerance to maintain glycemic control. (C)

**As per ESC 2022 guidelines:**
- Obtain preoperative measurement of HbA1c (if not obtained within the previous 3 months) in patients with diabetes or disturbed glucose metabolism. Postpone elective NCS, if safe and practical, in patients with HbA1c ≥ 8.5% (≥ 69 mmol/mol). (B)
- Obtain preoperative assessment for concomitant cardiac conditions in patients with diabetes with suspected or known coronary artery disease, as well as patients with autonomic neuropathy, retinopathy, or renal disease and scheduled to undergo intermediate- or high-risk NCS. (B)

### Patients with Renal Impairment

**As per ESC 2022 guidelines:**
- Obtain preoperative serum creatinine and GFR measurements to screen for renal disease in patients with known risk factors (age > 65 years, BMI > 30 kg/m², diabetes, hypertension, hyperlipidemia, CVD, or smoking) undergoing intermediate- or high-risk NCS. (B)
- Consider obtaining cystatin C measurement, if available, in patients with impaired eGFR (< 45-59 mL/min/1.73 m²) to confirm kidney disease. (C)
- Consider administering IV isotonic fluids for balanced hydration, using a minimal volume of contrast media, and using low-osmolar or iso-osmolar contrast media in patients with a renal disease requiring perioperative contrast-enhanced radiography. (C)

### Patients with Iron Deficiency Anemia
**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider initiating iron therapy (either oral or intravenous) preoperatively in patients with iron deficiency anemia undergoing elective NCS to reduce blood transfusions and to increase hemoglobin. (C)

### Patients with ACS

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Perform coronary revascularization as appropriate and defer elective NCS to reduce perioperative cardiovascular events in patients with ACS. (B)

**As per ESC 2022 guidelines:**
- Obtain diagnostic evaluation and perform therapeutic interventions in patients with ACS scheduled for NCS similar to patients with ACS in non-surgical settings, if NCS can safely be postponed (at least 3 months). (A)
- Consider deciding on the priorities for surgery by an expert team on a case-by-case basis in the unlikely combination of a life-threatening clinical condition requiring urgent NCS and non-ST-segment elevation ACS with an indication for revascularization. (C)

### Patients with Coronary Artery Disease - Management of Antiplatelets

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider continuing aspirin in selected patients with chronic coronary disease without prior PCI undergoing elective NCS when the risk of cardiac events outweighs the risk of bleeding. (C)
- Do not initiate aspirin routinely in patients with coronary artery disease without prior PCI undergoing elective noncarotid NCS. (D)

### Patients with Coronary Artery Disease - Coronary Artery Revascularization

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider performing coronary revascularization and deferring surgery to reduce perioperative cardiovascular events in patients with coronary artery disease and hemodynamically significant left main coronary artery stenosis ≥ 50% planning elective NCS. (C)
- Do not perform routine preoperative coronary revascularization to reduce perioperative cardiovascular events in patients with non-left main coronary artery disease planning NCS. (D)

**As per ESC 2022 guidelines:**
- Consider obtaining preoperative evaluation in patients with an indication for PCI by an expert team (surgeon and cardiologist) before elective NCS. (C)
- Consider performing myocardial revascularization before high-risk elective NCS, depending on the amount of ischemic myocardium, refractory symptoms, and findings at coronary angiography (as in the case of left main disease). (C)
- Do not perform routine myocardial revascularization before low- and intermediate-risk NCS in patients with chronic coronary syndrome. (D)
- Use new-generation drug-eluting stents over bare-metal stents and balloon angioplasty in patients with an indication for PCI before NCS. (A)

**As per ACC/AHA/SCAI 2022 guidelines:**
- Do not perform routine coronary revascularization solely for the reduction of perioperative cardiovascular events in patients with non-left main or noncomplex coronary artery disease undergoing NCS. (D)

**As per CCS 2017 guidelines:**
- Do not perform preoperative prophylactic coronary revascularization in patients with stable coronary artery disease undergoing NCS. (D)

**Landmark Trial: CARP**
In patients at increased risk for perioperative cardiac complications and clinically significant coronary artery disease, coronary artery revascularization was not superior to no revascularization with respect to the rate of death at a mean follow-up of 2.7 years.
*McFalls EO et al. N Engl J Med. 2004 Dec 30.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/15615804/)
Substitute aspirin when feasible in the perioperative period until oral anticoagulation can be safely reinitiated in patients with prior PCI requiring discontinuation of oral anticoagulation monotherapy before NCS.
### Patients after PCI - Management of Antiplatelets

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Continue aspirin (75-100 mg), if possible, to reduce the risk of cardiac events in patients with prior PCI undergoing NCS. (B)
- Continue dual antiplatelet therapy in patients with coronary artery disease requiring time-sensitive NCS within 30 days of PCI with bare-metal stent or < 3 months of PCI with drug-eluting stent, unless the risk of bleeding outweighs the benefit of preventing stent thrombosis. (B)
- Substitute aspirin when feasible in the perioperative period until oral anticoagulation can be safely reinitiated in patients with prior PCI requiring discontinuation of oral anticoagulation monotherapy before NCS. (B)
- Consider administering perioperative bridging with IV antiplatelet therapy in selected patients after PCI (< 6 months after drug-eluting stent placement or < 30 days after bare-metal stent placement) having a high thrombotic risk, if NCS cannot be deferred. (C)

### Patients after PCI - Timing of Surgery

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Delay elective NCS for a minimum of 14 days to minimize perioperative major adverse cardiac events in patients with recent coronary artery balloon angioplasty without stent placement. (B)
- Delay elective NCS for ≥ 12 months to minimize perioperative major adverse cardiac events in patients with drug-eluting stent PCI placed for ACS requiring noncardiac surgery with interruption of ≥ 1 antiplatelet agents. (B)
- Delay surgery for ≥ 6 months after PCI to minimize perioperative major adverse cardiac events in patients with drug-eluting stent PCI placed for chronic coronary disease requiring NCS with interruption of ≥ 1 antiplatelet agents. (B)
- Consider performing NCS ≥ 3 months after PCI in patients with drug-eluting stent PCI requiring time-sensitive NCS with interruption of ≥ 1 antiplatelet agents if the risk of delaying surgery outweighs the risk of major adverse cardiac events. (C)
- Avoid performing elective NCS requiring interruption of ≥ 1 antiplatelet agents in patients with a recent (< 30 days) bare-metal stent or drug-eluting stent PCI due to a high risk of stent thrombosis and ischemic complications. (D)

**As per ESC 2022 guidelines:**
- Delay elective NCS until 6 months after elective PCI and 12 months after an ACS. (A)
- Delay time-sensitive NCS until at least 1 month of dual antiplatelet therapy initiation after elective PCI. (B)

### Patients with HF

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider continuing chronic RAAS inhibitors for HFrEF perioperatively. (C)
- Withhold SGLT-2 inhibitors for 3-4 days before elective NCS in patients with HF to reduce the risk of perioperative metabolic acidosis. (B)
- Consider continuing guideline-directed medical therapy (excluding SGLT-2 inhibitors) in the perioperative period in patients with compensated HF undergoing NCS, unless contraindicated, to reduce the risk of worsening HF. (C)
- Coordinate with the LV assist device care team on the appropriate timing and perioperative considerations of elective NCS in patients with a LV assist device to mitigate the risk of perioperative major adverse cardiovascular events. (B)

**As per ESC 2022 guidelines:**
- Consider continuing RAAS inhibitors in the perioperative period in patients with stable HF. (C)
- Assess volume status and signs of organ perfusion regularly in patients with HF undergoing NCS. (B)
- Provide multidisciplinary team care involving ventricular assist device specialists for perioperative management of patients with HF receiving mechanical circulatory support. (B)

### Patients with Pulmonary Hypertension

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Continue targeted medical therapies for pulmonary arterial hypertension to reduce the risk of perioperative major adverse cardiovascular events in patients receiving stable doses and undergoing NCS. (B)
- Consider referring to or consulting with a specialized pulmonary hypertension center for patients with severe pulmonary hypertension undergoing elevated-risk NCS to support risk assessment, optimization, and postoperative management, including consideration of intensive care. (C)
- Consider obtaining invasive hemodynamic monitoring to guide intraoperative and postoperative care in patients with severe pulmonary hypertension undergoing elevated-risk NCS. (C)
- Consider administering short-acting inhaled pulmonary vasodilators, such as nitric oxide or aerosolized prostacyclins, to reduce elevated RV afterload and prevent acute decompensated right HF in patients with precapillary pulmonary hypertension undergoing elevated-risk NCS. (C)

**As per ESC 2022 guidelines:**
- Continue chronic therapy for pulmonary arterial hypertension in the perioperative period of NCS. (B)
- Consider administering inodilators (dobutamine, milrinone, levosimendan) to increase cardiac output and lower pulmonary vascular resistance in the perioperative period according to the patient's hemodynamic status. (C)
- Continue hemodynamic monitoring of patients with severe pulmonary arterial hypertension for at least 24 hours in the postoperative period. (B)
- Optimize the diuretic dose and, if necessary, administer IV prostacyclin analogs under the guidance of an experienced physician in patients with pulmonary arterial hypertension having progression of right HF in the postoperative period. (B)

### Patients with AAA

**As per ESC 2022 guidelines:**
- Do not obtain routine cardiac evaluation, coronary angiography, or cardiopulmonary exercise testing before elective surgery for AAA. (D)
- Obtain cardiac evaluation and optimize management before elective surgery for AAA in patients with poor functional capacity or significant risk factors or symptoms (such as moderate-to-severe angina pectoris, decompensated HF, valvular disease, and significant arrhythmia). (B)

### Patients with PAD

**As per ESC 2022 guidelines:**
- Do not obtain routine cardiac evaluation, coronary angiography, or cardiopulmonary exercise testing before elective surgery for PAD. (D)
- Obtain cardiac evaluation and optimize management before elective surgery for PAD in patients with poor functional capacity or significant risk factors or symptoms (such as moderate-to-severe angina pectoris, decompensated HF, valvular disease, and significant arrhythmia). (B)

### Patients with Valvular Heart Disease - General Principles

**As per ESC 2022 guidelines:**
- Obtain clinical and echocardiographic evaluation (if not obtained recently) in all patients with known or suspected valvular heart disease scheduled for elective intermediate- or high-risk NCS. (B)

**As per ACC/AHA 2021 guidelines:**
- Obtain preoperative echocardiography in patients with clinically suspected moderate or greater degrees of valvular stenosis or regurgitation undergoing NCS. (B)
- Perform valvular intervention before elective NCS to reduce perioperative risk if possible, depending on the urgency and risk of the noncardiac procedure, in patients meeting standard indications for intervention for valvular heart disease (replacement and repair) based on symptoms and disease severity. (B)

### Patients with Valvular Heart Disease - Aortic Stenosis

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Evaluate patients with severe aortic stenosis for the need for aortic valve intervention before elective NCS to reduce perioperative risk. (B)
- Obtain preoperative echocardiography to guide perioperative management in patients with suspected moderate or severe aortic stenosis undergoing elevated-risk NCS. (B)
- Consider proceeding with elective low-risk NCS in asymptomatic patients with moderate or severe aortic stenosis and normal LV systolic function as assessed by echocardiography within the past year. (C)
- Consider performing NCS early as clinically indicated in patients undergoing successful TAVI. (C)

**As per ESC 2022 guidelines:**
- Perform aortic valve replacement (SAVR or TAVI) in symptomatic patients with severe aortic valve stenosis scheduled for elective intermediate- or high-risk NCS. (B)
- Consider performing aortic valve replacement (SAVR or TAVI) after heart team discussion in asymptomatic patients with severe aortic valve stenosis scheduled for elective high-risk NCS. (C)
- Consider performing balloon aortic valvuloplasty before NCS as a bridge to definitive aortic valve repair in patients with severe symptomatic aortic valve stenosis requiring time-sensitive NCS or when TAVI and SAVR are unfeasible. (C)

**As per ACC/AHA 2021 guidelines:**
- Consider performing elective NCS in asymptomatic patients with moderate or greater degrees of aortic stenosis and normal LV systolic function. (C)

### Patients with Valvular Heart Disease - Mitral Stenosis

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Evaluate patients with severe MS for the need for mitral valve intervention before elective NCS. (B)
- Consider obtaining perioperative invasive hemodynamic monitoring to guide management and reduce the risk of cardiovascular complications in patients with severe MS unable to undergo mitral valve intervention before NCS. (C)
- Consider initiating perioperative heart-rate control (β-blockers, CCBs, ivabradine, digoxin) to prolong diastolic filling time and decrease perioperative cardiovascular complications in patients with severe MS unable to undergo mitral valve intervention before NCS. (C)
- Perform NCS after successful mitral valve transcatheter edge-to-edge repair as clinically indicated. (B)

**As per ESC 2022 guidelines:**
- Perform valve intervention (percutaneous mitral commissurotomy or surgery) before elective intermediate- or high-risk NCS in patients with moderate-to-severe rheumatic mitral valve stenosis and symptoms or systolic pulmonary artery pressure > 50 mmHg. (B)

**As per ACC/AHA 2021 guidelines:**
- Consider performing elective NCS in asymptomatic patients with moderate or greater degrees of rheumatic MS and pulmonary artery systolic pressure < 50 mmHg. (C)

### Patients with Valvular Heart Disease - Aortic Regurgitation

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Obtain preoperative echocardiography in patients with suspected moderate or severe valvular regurgitation before elective NCS to guide perioperative management. (B)
- Consider performing valvular intervention in patients with valvular heart disease meeting indications for valvular intervention based on clinical presentation and severity of regurgitation before elective elevated-risk NCS to reduce perioperative risk. (B)
- Consider performing elective NCS in asymptomatic patients with moderate or severe aortic regurgitation and normal LV systolic function (LVEF > 55%). (C)

**As per ESC 2022 guidelines:**
- Perform valve surgery before elective intermediate- or high-risk NCS in patients with symptomatic severe aortic valve regurgitation or asymptomatic severe aortic valve regurgitation and LVESD > 50 mm or LV end-systolic dimension index (LVESD/body surface area) > 25 mm/m² (in patients with small body size) or resting LVEF ≤ 50%. (B)

**As per ACC/AHA 2021 guidelines:**
- Consider performing elective NCS in asymptomatic patients with moderate or greater degrees of aortic regurgitation and normal LV systolic function. (C)

### Patients with Valvular Heart Disease - Mitral Regurgitation

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Obtain preoperative echocardiography in patients with suspected moderate or severe valvular regurgitation before elective NCS to guide perioperative management. (B)
- Consider performing valvular intervention in patients with valvular heart disease meeting indications for valvular intervention based on clinical presentation and severity of regurgitation before elective elevated-risk NCS to reduce perioperative risk. (B)
- Consider performing elective NCS in asymptomatic patients with moderate or severe MR, normal LV systolic function, and estimated pulmonary artery systolic pressure < 50 mmHg. (C)

**As per ESC 2022 guidelines:**
- Consider performing valve intervention (surgical or transcatheter) before intermediate- or high-risk NCS, if time allows, in patients with symptomatic severe primary mitral valve regurgitation or asymptomatic severe primary mitral valve regurgitation with LV dysfunction (LVESD ≥ 40 mm and/or LVEF ≤ 60%). (C)
- Consider performing valve intervention (transcatheter or surgical) before NCS in patients with severe secondary mitral valve regurgitation remaining symptomatic despite guideline-directed medical therapy (including CRT if indicated) with acceptable procedural risk. (C)

**As per ACC/AHA 2021 guidelines:**
- Consider performing elective NCS in asymptomatic patients with moderate or greater degrees of MR and normal LV systolic function with less than severe pulmonary hypertension (pulmonary artery systolic pressure < 50 mmHg). (C)

### Patients with Supraventricular Arrhythmias

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider treating potential underlying triggers contributing to AF and rapid ventricular response (sepsis, anemia, pain) in patients with rapid AF identified in the setting of NCS. (C)
- Consider initiating postoperative anticoagulation therapy in patients with new-onset AF identified in the setting of NCS after evaluating the competing risks associated with thromboembolism and perioperative bleeding. (C)
- Obtain outpatient follow-up for thromboembolic risk stratification and AF surveillance in patients with new-onset AF identified in the setting of NCS due to a high risk of AF recurrence. (B)

**As per ESC 2022 guidelines:**
- Continue antiarrhythmic drugs during the perioperative period in patients with SVT controlled by medication. (B)
- Consider performing ablation before high-risk, nonurgent NCS in symptomatic patients with recurrent or persistent SVT despite treatment. (C)
- Perform emergency electrical cardioversion in patients with AF with acute or worsening hemodynamic instability undergoing NCS. (B)
- Consider administering amiodarone for acute control of HR in patients with AF with hemodynamic instability. (C)

### Patients with Ventricular Arrhythmias

**As per ESC 2022 guidelines:**
- Perform ablation of arrhythmia before elective NCS in patients with symptomatic, monomorphic, sustained VT associated with myocardial scar, recurring despite optimal medical therapy. (B)
- Do not initiate treatment for asymptomatic premature ventricular contractions during NCS. (D)

### Patients with Cardiac Implantable Electronic Devices

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Develop a management plan before surgery for patients with cardiovascular implantable electronic devices undergoing elective NCS if electromagnetic interference is anticipated, including identification of the type of device (such as pacemaker, ICD, implantable monitor), manufacturer, and model. (B)
- Reprogram the pacemaker or place a magnet on the generator to provide an asynchronous mode in pacemaker-dependent patients undergoing surgeries above the umbilicus with anticipated electromagnetic interference to avoid pacing inhibition. (B)
- Reprogram the device in pacemaker-dependent patients with a transvenous ICD undergoing surgery above the umbilicus with anticipated electromagnetic interference. Reprogram the device or place a magnet on the generator to inhibit tachytherapies or inappropriate shocks if the patient is not pacemaker-dependent. (B)
- Restore device functioning in the postoperative period before hospital discharge in patients with a pacemaker or ICD reprogrammed to asynchronous pacing or having tachytherapies programmed off before surgery. (B)
- Reprogram the pacemakers to an asynchronous mode in pacemaker-dependent patients with leadless pacemakers undergoing surgeries with anticipated electromagnetic interference above the umbilicus. (B)
- Consider reprogramming the device or using a magnet to temporarily disable tachytherapies in patients with subcutaneous ICDs undergoing noncardiac or nonthoracic surgery with anticipated electromagnetic interference above the groin. (C)

**As per ESC 2022 guidelines:**
- Defer NCS and consider implanting a permanent pacemaker in patients having an indication for pacing according to current clinical practice guidelines. (B)
- Obtain continuous ECG monitoring in patients with temporarily deactivated ICDs and ensure they are accompanied by personnel skilled in early detection and treatment of arrhythmias during the perioperative period. Place transcutaneous pacing/defibrillation pads before NCS in high-risk patients (such as pacemaker-dependant patients or patients with ICD) or if access to the torso will be difficult during the procedure. (B)
- Re-check and perform necessary reprogramming as soon as possible after the procedure in all patients with cardiac implantable electronic devices reprogrammed before surgery. (B)
- Consider obtaining a cardiac implantable electronic device check-up and performing necessary reprogramming immediately before the procedure in high-risk patients with a cardiac implantable electronic device (such as an ICD or being pacing-dependant) undergoing NCS carrying a high probability of electromagnetic interference (such as involving unipolar electrosurgery above the umbilical area). (C)

### Patients with Cardiomyopathy

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Avoid factors aggravating or triggering dynamic outflow obstructions, such as positive inotropic agents, tachycardia, or reduced preload, to reduce the risk of hemodynamic instability in patients with HCM undergoing NCS. (D)

**As per ESC 2023 guidelines:**
- Obtain perioperative ECG monitoring in all patients with cardiomyopathy undergoing NCS. (B)
- Re-evaluate LV function with echocardiography (LVOTO in patients with HCM) and NT-proBNP/BNP, if not recently been obtained, in patients with cardiomyopathy and suspected or known HF scheduled for intermediate or high-risk NCS. (B)
- Refer patients with cardiomyopathy with high-risk genotypes or associated factors for arrhythmic or HF complications or severe LVOTO to a cardiomyopathy unit for additional specialized investigations before undergoing elective NCS. (B)
- Obtain an ECG and TTE before NCS in < 65 years old patients with a first-degree relative with cardiomyopathy, regardless of symptoms. (B)

### Patients with Pericardial Diseases

**As per ESC 2022 guidelines:**
- Consider deferring elective NCS in patients with acute pericarditis until complete resolution of the underlying process. (C)
- Avoid performing elective NCS procedures under general anesthesia until colchicine or the immunosuppressive treatment course for pericardial disease is completed. (D)

### Patients with Adult Congenital Heart Disease

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Obtain preoperative consultation with an adult congenital heart disease specialist for patients with intermediate- to elevated-risk congenital heart disease lesions undergoing elective NCS. (B)

**As per ESC 2022 guidelines:**
- Obtain consultation with an adult congenital heart disease specialist before intermediate- or high-risk surgery in adult patients with congenital heart disease. (B)
- Perform intermediate- and high-risk elective surgeries in a center with experience in the management of patients with adult congenital heart disease. (B)

### Patients with Patent Foramen Ovale

**As per ESC 2021 guidelines:**
- Do not screen for patent foramen ovale during preoperative evaluations for NCS in unselected healthy, asymptomatic patients. (D)
- Insufficient evidence regarding any form of primary prevention, pharmaceutical or interventional, for thrombotic systemic embolism in asymptomatic patients with a known patent foramen ovale. **[I]**
- Manage patients at high risk of perioperative thrombosis according to current clinical practice guidelines, irrespective of the presence of a patent foramen ovale. (B)
- Obtain routine screening for patent foramen ovale before surgery in all patients scheduled for neurosurgery in the sitting position. (B)
- Do not perform neurosurgery in the sitting position in patients with a patent foramen ovale and obtain close monitoring during neurosurgery in a horizontal surgical position. (D)
- Consider performing patent foramen ovale closure followed by neurosurgery at a later date after assessing the completeness of closure in selected patients with patent foramen ovale if the neurosurgical operation can be delayed 1-12 months (preferably 6-12) and: a) the sitting position is mandatory, b) a previous attempt at surgery in a prone or lateral position led to a venous air embolism. (C)

### Patients with Carotid Artery Disease - Preoperative Evaluation

**As per ESVS 2023 guidelines:**
- Do not obtain routine carotid imaging in asymptomatic patients undergoing noncardiac surgical procedures. (D)
- Obtain carotid artery imaging in patients undergoing elective NCS with a history of stroke or TIA within the preceding 6 months. (B)
- Obtain a comprehensive cardiovascular risk assessment to aid the consent process regarding the risk of perioperative stroke in patients undergoing major noncardiac surgical procedures. (B)

**As per ESC 2022 guidelines:**
- Do not obtain routine preoperative carotid artery imaging in patients undergoing NCS. (D)
- Obtain preoperative carotid artery and cerebral imaging in patients with a history of TIA or stroke in the previous 6 months with no history of ipsilateral revascularization. (B)

### Patients with Carotid Artery Disease - Preoperative Statins and Antithrombotics

**As per ESVS 2023 guidelines:**
- Do not discontinue statin therapy before surgery in patients with asymptomatic 50-99% carotid artery stenoses undergoing a major noncardiac procedure. Withhold antithrombotic therapy based on an assessment of thromboembolic and hemorrhagic risks. (D)

### Patients with Carotid Artery Disease - Carotid Revascularization

**As per ESVS 2023 guidelines:**
- Do not perform prophylactic carotid endarterectomy or carotid artery stenting in patients with an asymptomatic 50-99% carotid artery stenosis undergoing major NCS. (D)
- Consider performing carotid revascularization before noncardiac surgical procedure in patients with a history of stroke or TIA in the preceding 6 months attributable to an ipsilateral 50-99% carotid artery stenosis and scheduled to undergo elective NCS. (B)

**As per ESC 2022 guidelines:**
- Consider performing carotid revascularization in patients with carotid artery disease undergoing NCS according to the same indications as for other patients with carotid artery stenosis. (C)

### Patients with Stroke

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider delaying elective NCS for ≥ 3 months after the most recent cerebrovascular event in patients with a history of stroke or TIA to reduce the incidence of recurrent stroke, major adverse cardiovascular events, or both. (C)

**As per ESVS 2023 guidelines:**
- Delay elective NCS by 6 months where possible in patients with a history of stroke and no significant carotid artery disease. Individualize the decision on proceeding with semi-urgent elective surgery based on the underlying pathology. (B)

## Patient Education

### General Counseling

**As per ESC 2022 guidelines:**
- Provide patients with individualized instructions for preoperative and postoperative changes in medications, in verbal and written formats with clear and concise directions. (B)
- Consider providing a structured information list (such as a checklist to help with common issues) in patients with CVD or at high risk of cardiovascular complications scheduled for NCS. (C)

**As per CCS 2017 guidelines:**
- Communicate perioperative cardiac risks to patients undergoing NCS, in the format of expected event rate among 100 patients or the range of risk consistent with the 95% confidence interval of the risk estimate. (B)

## Follow-up and Surveillance

### Postoperative Cardiac Monitoring - General Principles

**As per ESC 2022 guidelines:**
- Ensure high awareness of perioperative cardiovascular complications and obtain surveillance for perioperative myocardial infarction in patients undergoing intermediate- or high-risk NCS. (B)
- Obtain systematic perioperative myocardial infarction evaluation to identify the underlying pathophysiology and define therapy. (B)

### Postoperative Cardiac Monitoring - ECG

**As per CCS 2017 guidelines:**
- Consider obtaining a postoperative ECG in the postanesthetic care unit in patients with elevated NT-proBNP/BNP levels before surgery or, if there is no NT-proBNP/BNP level measurement before surgery, in patients having a RCRI score ≥ 1, aged 45-64 years with significant CVD, or aged ≥ 65 years. (C)

### Postoperative Cardiac Monitoring - Troponin

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider obtaining cardiac troponin at 24 and 48 hours after surgery to identify myocardial injury in patients with known CVD, symptoms of CVD, or age ≥ 65 years with cardiovascular risk factors undergoing elevated-risk NCS. (C)
- Do not obtain routine postoperative screening with cardiac troponin levels in patients without signs or symptoms suggestive of myocardial ischemia or myocardial infarction undergoing low-risk NCS. (D)

**As per ESAIC 2023 guidelines:**
- Consider obtaining a routine postoperative measurement of cardiac troponins to help evaluate the risk of certain adverse outcomes, particularly predicting 30-day all-cause mortality, after NCS. (C)
- Consider obtaining cardiac troponins in addition to clinical risk scores for the prediction of certain postoperative events. (C)

**As per CCS 2017 guidelines:**
- Obtain daily troponin measurements for 48-72 hours after NCS in patients with a baseline risk > 5% for cardiovascular death or nonfatal myocardial infarction at 30 days after surgery (patients with an elevated NT-proBNP/BNP measurement before surgery or, if there is no NT-proBNP/BNP measurement before surgery, in patients having a RCRI score ≥ 1, aged 45-64 years with significant CVD, or aged ≥ 65 years). (B)

### Management of Postoperative Complications - Myocardial Injury/Ischemia

**As per ACC/ACS/AHA/…/SVM 2024 guidelines:**
- Consider obtaining outpatient follow-up for optimization of cardiovascular risk factors in patients developing myocardial injury after NCS, especially in patients not previously known to have excess cardiovascular risk. (C)
- Consider initiating antithrombotic therapy to reduce thromboembolic events in patients developing myocardial injury after NCS. (C)
- Consider initiating guideline-directed medical therapy, including consideration of invasive coronary angiography, in patients with STEMI after NCS as recommended for patients with spontaneous myocardial infarction, balancing bleeding and thrombotic risks with the severity of the clinical presentation. (B)
- Initiate medical therapy in patients with NSTEMI after NCS, taking into account postoperative bleeding risks and hemodynamic status. (B)
- Consider obtaining invasive coronary angiography in patients with NSTEMI after NCS, balancing bleeding and thrombotic risks with the severity of clinical presentation. (C)

**As per ESC 2022 guidelines:**
- Manage postoperative STEMI, non-ST-segment elevation ACS, and acute HF according to current clinical practice guidelines for the nonsurgical setting after interdisciplinary discussion with the surgeon about bleeding risk. (B)
- Consider initiating dabigatran 110 mg PO BID from ∼ 1 week after surgery in patients with myocardial injury following NCS and low bleeding risk. (C)

**Landmark Trial: MANAGE**
In patients who had undergone noncardiac surgery and were within 35 days of myocardial injury after noncardiac surgery, dabigatran was superior to placebo with respect to major vascular complications.
*Devereaux PJ et al. Lancet. 2018 Jun 9.* [PubMed: 29900874](https://pubmed.ncbi.nlm.nih.gov/29900874/)

**As per CCS 2017 guidelines:**
- Initiate long-term aspirin and statins in patients with myocardial injury or myocardial infarction after NCS. (B)

### Management of Postoperative Complications - Arrhythmias

**As per ESC 2022 guidelines:**
- Manage postoperative tachyarrhythmias according to current clinical practice guidelines for the nonsurgical setting, after interdisciplinary discussion with the surgeon about bleeding risk. (B)
- Consider initiating long-term OAC therapy in all patients with postoperative AF after NCS at risk of stroke, taking into account the anticipated net clinical benefit of OAC therapy and informed patient preferences. (C)

### Management of Postoperative Complications - Pulmonary Embolism

**As per ESC 2022 guidelines:**
- Initiate anticoagulation without delay while diagnostic evaluation is in progress in patients with postoperative PE of high or intermediate clinical probability and low bleeding risk. (B)
- Prefer DOACs over VKAs in patients with a postoperative indication for oral anticoagulation. (A)
- Continue postoperative oral anticoagulation for PE for at least 3 months. (B)

## References

1. Annemarie Thompson, Kirsten E Fleischmann, Nathaniel R Smilowitz et al. 2024 AHA / ACC / ACS / ASNC / HRS / SCA / SCCT / SCMR / SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Nov 5;150(19):e351-e442. [PubMed: 39316661](https://pubmed.ncbi.nlm.nih.gov/39316661/)

2. Sigrun Halvorsen, Julinda Mehilli, Salvatore Cassese et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022 Oct 14;43(39):3826-3924. [PubMed: 36017553](https://pubmed.ncbi.nlm.nih.gov/36017553/)

3. Catherine M Otto, Rick A Nishimura, Robert O Bonow et al. 2020 ACC / AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2021 Aug;162(2):e183-e353. [PubMed: 33972115](https://pubmed.ncbi.nlm.nih.gov/33972115/)

4. Giovanna Lurati Buse, Bernardo Bollen Pinto, Fernando Abelha et al. ESAIC focused guideline for the use of cardiac biomarkers in perioperative risk evaluation. Eur J Anaesthesiol. 2023 Dec 1;40(12):888-927. [PubMed: 37703077](https://pubmed.ncbi.nlm.nih.gov/37703077/)

5. Ross Naylor, Barbara Rantner, Stefano Ancetti et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023 Jan;65(1):7-111. [Open Access]

6. James D Douketis, Alex C Spyropoulos, M Hassan Murad et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline Executive Summary. Chest. 2022 Aug 10;S0012-3692(22)01364-2. [Open Access]

7. Emmanuelle Duceppe, Joel Parlow, Paul MacDonald et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Can J Cardiol. 2017 Jan;33(1):17-32. [PubMed: 28024555](https://pubmed.ncbi.nlm.nih.gov/28024555/)

8. Christian Pristipino, Peter Germonpré, Danilo Toni et al. European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. EuroIntervention. 2021 Aug 6;17(5):e367-e375. [PubMed: 33769927](https://pubmed.ncbi.nlm.nih.gov/33769927/)

9. Elena Arbelo, Alexandros Protonotarios, Juan R Gimeno et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. [PubMed: 37622657](https://pubmed.ncbi.nlm.nih.gov/37622657/)

10. Jennifer S Lawton, Jacqueline E Tamis-Holland, Sripal Bangalore et al. 2021 ACC / AHA / SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Jan 18;145(3):e18-e114. [PubMed: 34882435](https://pubmed.ncbi.nlm.nih.gov/34882435/)

11. Fleisher LA, Fleischmann KE, Auerbach AD et al. 2014 ACC / AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 9;130(24):2215-45. [Open Access]

12. Goff DC Jr, Lloyd-Jones DM, Bennett G et al. 2013 ACC / AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73. [Open Access]

13. Fihn SD, Blankenship JC, Alexander KP et al. 2014 ACC / AHA / AATS / PCNA / SCAI / STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014 Nov 4;64(18):1929-49. [Open Access]

